-+ 0.00%
-+ 0.00%
-+ 0.00%

Xcell Therapeutics Q3 Net Loss Widens 32.3% Year Over Year

PUBT·11/06/2026 07:50:35
Listen to the news
Xcell Therapeutics Q3 Net Loss Widens 32.3% Year Over Year
  • Xcell Therapeutics posted a third-quarter 2026 operating loss of KRW 2.98 billion, widening 25.6% year over year.
  • Revenue rose 217.9% year over year to KRW 1.06 billion.
  • Sequentially, revenue fell 45.1%, while the operating loss widened 8.3%.
  • Net loss widened 32.3% year over year to KRW 3.06 billion.
  • Revenue for January-September 2026 reached KRW 4.02 billion, up 354.2% year over year.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xcell Therapeutics Inc. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261106900711), on November 06, 2026, and is solely responsible for the information contained therein.